Document Detail


Differential effects of four xylidine derivatives in the model of ischemia- and re-perfusion-induced arrhythmias in rats in vivo.
MedLine Citation:
PMID:  20615402     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of our study was to find the most effective xylidine derivative, which reduced mortality, reduced incidence and duration of severe arrhythmias and had a beneficial influence on hemodynamic parameters in an in vivo setting. We compared the action of lidocaine, articaine, ropivacaine and mepivacaine in a dose 2.5 or 5mg/kg/ml/h infused from 10min before left anterior descending coronary artery occlusion until the end of the experiment. In the rat ischemia- and re-perfusion-induced arrhythmia models, the following parameters were measured or calculated: mortality index, ventricular fibrillation and tachycardia incidence and duration, systolic, diastolic and mean arterial blood pressure, heart rate and pressure rate product. Lidocaine produced the most significant reduction in mortality index (P<0.05) after both doses. At the higher dose, lidocaine and articaine shortened ventricular fibrillation and tachycardia duration (P<0.05-P<0.001), while ropivacaine prolonged them. A hypertensive effect was observed after a lower dose of lidocaine during occlusion and early re-perfusion as compared to others (P<0.05). Beneficial effects were mainly observed with lidocaine, which protected against sudden cardiac death. The novelty was lidocaine's dose independent protection against blood pressure drop in early re-perfusion, which could be linked to the effects observed on the other end-points. Articaine showed beneficial effects but they weren't as pronounced as that of lidocaine. Nevertheless, in the light of our results, articaine could supposedly be used as a substitute for lidocaine in patients with hypertension.
Authors:
Tadeusz F Krzemiński; Katarzyna Mitrega; Michał Zorniak; Maurycy Porc
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2010-07-06
Journal Detail:
Title:  European journal of pharmacology     Volume:  644     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-08-17     Completed Date:  2010-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  120-7     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier B.V. All rights reserved.
Affiliation:
Department of Pharmacology, Cardiovascular Research Division, Medical University of Silesia, ul. Jordana 19, 41-808 Zabrze, Poland. tadkrzem@ka.onet.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amides / administration & dosage,  pharmacology
Anesthetics, Local / administration & dosage,  pharmacology*
Animals
Anti-Arrhythmia Agents / pharmacology*
Arrhythmias, Cardiac / drug therapy*,  etiology,  mortality
Blood Pressure / drug effects
Carticaine / administration & dosage,  pharmacology
Disease Models, Animal
Dose-Response Relationship, Drug
Heart Rate / drug effects
Lidocaine / administration & dosage,  pharmacology
Male
Mepivacaine / administration & dosage,  pharmacology
Myocardial Reperfusion Injury / complications*
Rats
Rats, Sprague-Dawley
Severity of Illness Index
Tachycardia / drug therapy,  etiology
Time Factors
Ventricular Fibrillation / drug therapy,  etiology
Chemical
Reg. No./Substance:
0/Amides; 0/Anesthetics, Local; 0/Anti-Arrhythmia Agents; 137-58-6/Lidocaine; 23964-58-1/Carticaine; 84057-95-4/ropivacaine; 96-88-8/Mepivacaine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Actions of thalidomide in producing vascular relaxations.
Next Document:  Acidic stress facilitates tyrosine phosphorylation of HLJ1 to associate with actin cytoskeleton in l...